{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:45:09Z","timestamp":1793051109454,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People\u2019s Republic of China","doi-asserted-by":"publisher","award":["2017YFA0205501"],"award-info":[{"award-number":["2017YFA0205501"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-34487-1","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:40:59Z","timestamp":1767786059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted drug delivery to AML by OFA\/iLRP aptamer guided DNA nanostructure"],"prefix":"10.1038","volume":"16","author":[{"given":"Yacong","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjiao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xundou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Da","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"34487_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu, H. Emerging agents and regimens for aml. J. Hematol. Oncol. 14, 49 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"34487_CR2","doi-asserted-by":"publisher","first-page":"2196482","DOI":"10.1080\/16078454.2023.2196482","volume":"28","author":"MZ Mohamed Jiffry","year":"2023","unstructured":"Mohamed Jiffry, M. Z. et al. A review of treatment options employed in relapsed\/refractory aml. Hematology 28, 2196482 (2023).","journal-title":"Hematology"},{"key":"34487_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"34487_CR4","doi-asserted-by":"publisher","first-page":"n2026","DOI":"10.1136\/bmj.n2026","volume":"375","author":"LF Newell","year":"2021","unstructured":"Newell, L. F. & Cook R.J. Advances in acute myeloid leukemia. BMJ 375, n2026 (2021).","journal-title":"BMJ"},{"key":"34487_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","volume":"45","author":"M Forsberg","year":"2024","unstructured":"Forsberg, M. & Konopleva, M. Aml treatment: conventional chemotherapy and emerging novel agents. Trends Pharmacol. Sci. 45, 430\u2013448 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"34487_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali, R. S., Pratz, K. W. & Lai, C. Recent advances in targeted therapies in acute myeloid leukemia. J. Hematol. Oncol. 16, 29 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"34487_CR7","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia, A. et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl. J. Med. 384, 1529\u20131541 (2021).","journal-title":"N Engl. J. Med."},{"key":"34487_CR8","doi-asserted-by":"publisher","first-page":"e202200032","DOI":"10.1002\/cmdc.202200032","volume":"17","author":"CS Chia","year":"2022","unstructured":"Chia, C. S. .B. A patent review on fda-approved antibody-drug conjugates, their linkers and drug payloads. ChemMedChem 17, e202200032 (2022).","journal-title":"ChemMedChem"},{"key":"34487_CR9","doi-asserted-by":"crossref","unstructured":"Baah, S., Laws, M. & Rahman, K. M. Antibody-drug conjugates-a tutorial review. Molecules 26 (2021).","DOI":"10.3390\/molecules26102943"},{"key":"34487_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.molimm.2021.08.013","volume":"139","author":"F Martinez-Cortes","year":"2021","unstructured":"Martinez-Cortes, F. et al. Generation of cancer vaccine immunogens derived from oncofetal antigen (ofa\/ilrp) using variable epitope libraries tested in an aggressive breast cancer model. Mol. Immunol. 139, 65\u201375 (2021).","journal-title":"Mol. Immunol."},{"key":"34487_CR11","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1182\/blood-2003-01-0198","volume":"102","author":"S Siegel","year":"2003","unstructured":"Siegel, S. et al. Induction of cytotoxic t-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 102, 4416\u20134423 (2003).","journal-title":"Blood"},{"key":"34487_CR12","first-page":"3888","volume":"50","author":"K Mafune","year":"1990","unstructured":"Mafune, K. et al. Expression of a Mr 32,000 laminin-binding protein messenger Rna in human colon carcinoma correlates with disease progression. Cancer Res. 50, 3888\u20133891 (1990).","journal-title":"Cancer Res."},{"key":"34487_CR13","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.jmb.2008.02.004","volume":"378","author":"C Zuber","year":"2008","unstructured":"Zuber, C. et al. Invasion of tumorigenic ht1080 cells is impeded by blocking or downregulating the 37-kda\/67-kda laminin receptor. J. Mol. Biol. 378, 530\u2013539 (2008).","journal-title":"J. Mol. Biol."},{"key":"34487_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1210\/me.2010-0334","volume":"25","author":"SL Poon","year":"2011","unstructured":"Poon, S. L., Klausen, C., Hammond, G. L. & Leung, P. C. 37-kda laminin receptor precursor mediates gnrh-ii-induced mmp-2 expression and invasiveness in ovarian cancer cells. Mol. Endocrinol. 25, 327\u2013338 (2011).","journal-title":"Mol. Endocrinol."},{"key":"34487_CR15","doi-asserted-by":"publisher","first-page":"e57409","DOI":"10.1371\/journal.pone.0057409","volume":"8","author":"K Moodley","year":"2013","unstructured":"Moodley, K. & Weiss, S. F. Downregulation of the non-integrin laminin receptor reduces cellular viability by inducing apoptosis in lung and cervical cancer cells. PLoS One. 8, e57409 (2013).","journal-title":"PLoS One"},{"key":"34487_CR16","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1158\/1078-0432.CCR-08-1102","volume":"14","author":"J Greiner","year":"2008","unstructured":"Greiner, J., Bullinger, L., Guinn, B. A., Dohner, H. & Schmitt, M. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin. Cancer Res. 14, 7161\u20137166 (2008).","journal-title":"Clin. Cancer Res."},{"key":"34487_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s13205-018-1234-y","volume":"8","author":"B Liu","year":"2018","unstructured":"Liu, B., Kong, Q., Zhang, D. & Yan, L. Codon optimization significantly enhanced the expression of human 37-kda Ilrp in Escherichia coli. 3 Biotech. 8, 210 (2018).","journal-title":"3 Biotech."},{"key":"34487_CR18","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1016\/j.biomaterials.2009.02.022","volume":"30","author":"AL Barsoum","year":"2009","unstructured":"Barsoum, A. L. et al. Production, safety and antitumor efficacy of Recombinant oncofetal antigen\/immature laminin receptor protein. Biomaterials 30, 3091\u20133099 (2009).","journal-title":"Biomaterials"},{"key":"34487_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/mt.2009.199","volume":"18","author":"J Scheiman","year":"2010","unstructured":"Scheiman, J., Tseng, J. C., Zheng, Y. & Meruelo, D. Multiple functions of the 37\/67-kd laminin receptor make it a suitable target for novel cancer gene therapy. Mol. Ther. 18, 63\u201374 (2010).","journal-title":"Mol. Ther."},{"key":"34487_CR20","doi-asserted-by":"publisher","first-page":"12471","DOI":"10.1021\/acs.chemrev.3c00377","volume":"123","author":"C Ji","year":"2023","unstructured":"Ji, C. et al. Aptamer-protein interactions: from regulation to biomolecular detection. Chem. Rev. 123, 12471\u201312506 (2023).","journal-title":"Chem. Rev."},{"key":"34487_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/5584_2022_732","volume":"1409","author":"HB Woldekidan","year":"2023","unstructured":"Woldekidan, H. B., Woldesemayat, A. A., Adam, G. & Tafesse, M. Thimiri Govinda Raj, D.B. Aptamer-based tumor-targeted diagnosis and drug delivery. Adv. Exp. Med. Biol. 1409, 173\u2013192 (2023).","journal-title":"Adv. Exp. Med. Biol."},{"key":"34487_CR22","first-page":"161","volume":"174","author":"A Eilers","year":"2020","unstructured":"Eilers, A., Witt, S. & Walter, J. Aptamer-modified nanoparticles in medical applications. Adv. Biochem. Eng. Biotechnol. 174, 161\u2013193 (2020).","journal-title":"Adv. Biochem. Eng. Biotechnol."},{"key":"34487_CR23","first-page":"BE01","volume":"10","author":"A Parashar","year":"2016","unstructured":"Parashar, A. Aptamers in therapeutics. J. Clin. Diagn. Res. 10, BE01\u201306 (2016).","journal-title":"J. Clin. Diagn. Res."},{"key":"34487_CR24","doi-asserted-by":"publisher","first-page":"7343","DOI":"10.1038\/s41598-019-43910-3","volume":"9","author":"Y An","year":"2019","unstructured":"An, Y. et al. Selection of a novel DNA aptamer against ofa\/ilrp for targeted delivery of doxorubicin to aml cells. Sci. Rep. 9, 7343 (2019).","journal-title":"Sci. Rep."},{"key":"34487_CR25","first-page":"1106","volume":"30","author":"E Yaghoobi","year":"2022","unstructured":"Yaghoobi, E. et al. A multi-storey DNA nanostructure containing doxorubicin and as1411 aptamer for targeting breast cancer cells. J. Drug Target. 30, 1106\u20131112 (2022).","journal-title":"J. Drug Target."},{"key":"34487_CR26","doi-asserted-by":"crossref","unstructured":"Esawi, E. et al. Aptamer-aptamer chimera for targeted delivery and atp-responsive release of doxorubicin into cancer cells. Int J. Mol. Sci 22 (2021).","DOI":"10.3390\/ijms222312940"},{"key":"34487_CR27","doi-asserted-by":"publisher","first-page":"e2300097","DOI":"10.1002\/smll.202300097","volume":"19","author":"CE Callmann","year":"2023","unstructured":"Callmann, C. E., Vasher, M. K., Das, A., Kusmierz, C. D. & Mirkin, C. A. In vivo behavior of ultrasmall spherical nucleic acids. Small 19, e2300097 (2023).","journal-title":"Small"},{"key":"34487_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41570-021-00251-y","volume":"5","author":"AR Chandrasekaran","year":"2021","unstructured":"Chandrasekaran, A. R. Nuclease resistance of DNA nanostructures. Nat. Rev. Chem. 5, 225\u2013239 (2021).","journal-title":"Nat. Rev. Chem."},{"key":"34487_CR29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/17425247.2022.2063835","volume":"19","author":"C Asakiya","year":"2022","unstructured":"Asakiya, C. et al. Current progress of mirna-derivative nucleotide drugs: Modifications, delivery systems, applications. Expert Opin. Drug Deliv. 19, 435\u2013450 (2022).","journal-title":"Expert Opin. Drug Deliv"},{"key":"34487_CR30","doi-asserted-by":"publisher","first-page":"126245","DOI":"10.1016\/j.ijbiomac.2023.126245","volume":"251","author":"X Li","year":"2023","unstructured":"Li, X. et al. Thermodynamic and cellular studies of doxorubicin\/daunorubicin loaded by a DNA tetrahedron for diagnostic imaging, chemotherapy, and gene therapy. Int. J. Biol. Macromol. 251, 126245 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"34487_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/17425247.2019.1575808","volume":"16","author":"LY Wan","year":"2019","unstructured":"Wan, L. Y. et al. An exploration of aptamer internalization mechanisms and their applications in drug delivery. Expert Opin. Drug Deliv. 16, 207\u2013218 (2019).","journal-title":"Expert Opin. Drug Deliv"},{"key":"34487_CR32","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","volume":"10","author":"NJ Short","year":"2020","unstructured":"Short, N. J. et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 10, 506\u2013525 (2020).","journal-title":"Cancer Discov"},{"key":"34487_CR33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver, N. et al. Efficacy, safety, and biomarkers of response to Azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: A nonrandomized, open-label, phase Ii study. Cancer Discov. 9, 370\u2013383 (2019).","journal-title":"Cancer Discov"},{"key":"34487_CR34","doi-asserted-by":"publisher","first-page":"107077","DOI":"10.1016\/j.leukres.2023.107077","volume":"129","author":"W Aiman","year":"2023","unstructured":"Aiman, W. et al. Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials. Leuk. Res. 129, 107077 (2023).","journal-title":"Leuk. Res."},{"key":"34487_CR35","doi-asserted-by":"publisher","first-page":"e438662","DOI":"10.1200\/EDBK_438662","volume":"44","author":"Y Abaza","year":"2024","unstructured":"Abaza, Y., McMahon, C. & Garcia, J. S. Advancements and challenges in the treatment of aml. Am. Soc. Clin. Oncol. Educ. Book. 44, e438662 (2024).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"34487_CR36","doi-asserted-by":"crossref","unstructured":"Pommert, L. & Tarlock, K. The evolution of targeted therapy in pediatric aml: Gemtuzumab ozogamicin, flt3\/idh\/bcl2 inhibitors, and other therapies. Hematology 2022, 603\u2013610 (2022).","DOI":"10.1182\/hematology.2022000358"},{"key":"34487_CR37","doi-asserted-by":"crossref","unstructured":"Hafeez, U., Parakh, S., Gan, H. K. & Scott, A. M. Antibody-drug conjugates for cancer therapy. Molecules 25 (2020).","DOI":"10.3390\/molecules25204764"},{"key":"34487_CR38","first-page":"3","volume":"11","author":"MR Nejadmoghaddam","year":"2019","unstructured":"Nejadmoghaddam, M. R. et al. Antibody-drug conjugates: possibilities and challenges. Avicenna J. Med. Biotechnol. 11, 3\u201323 (2019).","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"34487_CR39","doi-asserted-by":"crossref","unstructured":"Lucas, C. R. et al. DNA Origami nanostructures elicit dose-dependent immunogenicity and are nontoxic up to high doses in vivo. Small 18 (2022).","DOI":"10.1002\/smll.202108063"},{"key":"34487_CR40","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1039\/D3BM01311A","volume":"12","author":"C Li","year":"2023","unstructured":"Li, C. et al. Macrophage-hitchhiked arsenic\/ab bionic preparations for liver cancer. Biomater. Sci. 12, 187\u2013198 (2023).","journal-title":"Biomater. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34487-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34487-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34487-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:58:26Z","timestamp":1770026306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34487-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34487"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34487-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4377"}}